Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Neprilysin is a neutral endopeptidase and its inhibition increases bioavailability of natriuretic peptides, bradykinin, and substance P, resulting in natriuretic, vasodilatatory, and anti-proliferative effects. In concert, these effects are prone to produce a powerful ventricular unloading and antihypertensive response. LCZ696 (Valsartan/sacubitril) is a first-in-class angiotensin II-receptor neprilysin inhibitor. LCZ696 is a novel drug not only for the treatment of heart failure but it is also likely to be a useful antihypertensive drug and may have a preferential effect on systolic pressure. This review discusses (i) the mechanism of action, pharmacokinetics, and pharmacodynamics of this novel drug, (ii) the efficacy, safety, and tolerability of LCZ696 in treatment of hypertension from the available trials, (iii) evidence from other contemporary trials on combined Neprilysin inhibitors, (iv) future trials and areas of research to identify hypertensive patient populations that would most benefit from LCZ696.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957 · cited 1×
“LCZ696 showed no significant change in heart rate from baseline in any of the trials.(22,23,27,28) Ruilope et al.”
BackgroundMakani, H., Messerli, F. H., Romero, J., Wever-Pinzon, O., Korniyenko, A., Berrios, R. S., & Bangalore, S. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.034 · Cited by 175 · cited 1×
“5 In contrast to omapatrilat, in LCZ696, the ACE inhibition has been replaced with an angiotensin II-receptor blocker (ARB) which has lesser effect on bradykinin(14) and thus a lower risk of angioedema.(15,16) Conceptually, this drug provides the vasodilatory and natriuretic properties of NPs concomitant with inhibito…”
MethodSelf-citationFryer, R. M., Segreti, J., Banfor, P. N., Widomski, D. L., Backes, B. J., Lin, C. W., Ballaron, S. J., Cox, B. F., Trevillyan, J. M., Reinhart, G. A., et al. (2008) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707641 · Cited by 130 · cited 1×
“5 In contrast to omapatrilat, in LCZ696, the ACE inhibition has been replaced with an angiotensin II-receptor blocker (ARB) which has lesser effect on bradykinin(14) and thus a lower risk of angioedema.(15,16) Conceptually, this drug provides the vasodilatory and natriuretic properties of NPs concomitant with inhibito…”
Method
Cited by
The Transition From Hypertension to Heart Failure
Messerli, F. H., Rimoldi, S. F., & Bangalore, S. (2017) · JACC: Heart Failure · doi:10.1016/j.jchf.2017.04.012 · Cited by 539
Self-citationNocturnal Hypertension: New Technology and Evidence
Kario, K. (2018) · Hypertension · doi:10.1161/hypertensionaha.118.10971 · Cited by 298
Self-citationJackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab499 · Cited by 156
Kario, K. (2016) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2016.04.001 · Cited by 144
Self-citation
Metadata
- Authors
- Bavishi, C., Messerli, F. H., Kadosh, B., Ruilope, L. M., & Kario, K.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-21
- Volume
- 36
- Issue
- 30
- Pages
- 1967-1973
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2165831607
- Cited by
- 110
- References
- 4
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. https://app.cochat.ai/papers/10.1093/eurheartj/ehv142
- The paper
- Bavishi, C., Messerli, F. H., Kadosh, B., Ruilope, L. M., & Kario, K. (2015). Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv142
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.